320 related articles for article (PubMed ID: 8586461)
1. Tumor antigens in astrocytic gliomas.
Kurpad SN; Zhao XG; Wikstrand CJ; Batra SK; McLendon RE; Bigner DD
Glia; 1995 Nov; 15(3):244-56. PubMed ID: 8586461
[TBL] [Abstract][Full Text] [Related]
2. Aspects of immunobiology and immunotherapy and uses of monoclonal antibodies and biologic immune modifiers in human gliomas.
Lee Y; Bigner DD
Neurol Clin; 1985 Nov; 3(4):901-17. PubMed ID: 2417097
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas.
Wikstrand CJ; Hale LP; Batra SK; Hill ML; Humphrey PA; Kurpad SN; McLendon RE; Moscatello D; Pegram CN; Reist CJ
Cancer Res; 1995 Jul; 55(14):3140-8. PubMed ID: 7606735
[TBL] [Abstract][Full Text] [Related]
4. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of local immunoresistance in glioma.
Albesiano E; Han JE; Lim M
Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963
[TBL] [Abstract][Full Text] [Related]
6. The class III variant of the epidermal growth factor receptor (EGFRvIII): characterization and utilization as an immunotherapeutic target.
Wikstrand CJ; Reist CJ; Archer GE; Zalutsky MR; Bigner DD
J Neurovirol; 1998 Apr; 4(2):148-58. PubMed ID: 9584952
[TBL] [Abstract][Full Text] [Related]
7. Antigenic heterogeneity of human brain tumors defined by monoclonal antibodies.
Stavrou D; Bise K; Groeneveld J; Stocker U; Kretzschmar HA; Keiditsch E; Mehraein P
Anticancer Res; 1989; 9(6):1489-96. PubMed ID: 2697177
[TBL] [Abstract][Full Text] [Related]
8. Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo.
Wikstrand CJ; Longee DC; McLendon RE; Fuller GN; Friedman HS; Fredman P; Svennerholm L; Bigner DD
Cancer Res; 1993 Jan; 53(1):120-6. PubMed ID: 8416736
[TBL] [Abstract][Full Text] [Related]
9. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma.
Sonabend AM; Dana K; Lesniak MS
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S45-50. PubMed ID: 18076318
[TBL] [Abstract][Full Text] [Related]
10. Retrovirally engineered T-cell-based immunotherapy targeting type III variant epidermal growth factor receptor, a glioma-associated antigen.
Ohno M; Natsume A; Ichiro Iwami K; Iwamizu H; Noritake K; Ito D; Toi Y; Ito M; Motomura K; Yoshida J; Yoshikawa K; Wakabayashi T
Cancer Sci; 2010 Dec; 101(12):2518-24. PubMed ID: 20880333
[TBL] [Abstract][Full Text] [Related]
11. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.
Wikstrand CJ; McLendon RE; Friedman AH; Bigner DD
Cancer Res; 1997 Sep; 57(18):4130-40. PubMed ID: 9307304
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for human glioma: innovative approaches and recent results.
Hussain SF; Heimberger AB
Expert Rev Anticancer Ther; 2005 Oct; 5(5):777-90. PubMed ID: 16221048
[TBL] [Abstract][Full Text] [Related]
13. [Monoclonal immunotherapy with human monoclonal antibody(CLN-IgG) in glioma patients].
Kubo O; Takakura K
Nihon Rinsho; 2002 Mar; 60(3):497-503. PubMed ID: 11904965
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cell-based immunotherapy for malignant gliomas.
Akasaki Y; Black KL; Yu JS
Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
[TBL] [Abstract][Full Text] [Related]
15. Tumor markers of the central nervous system.
Birkmayer GD
Cancer Detect Prev; 1981; 4(1-4):231-8. PubMed ID: 7349780
[TBL] [Abstract][Full Text] [Related]
16. Tumor immunology: a neurosurgical perspective. II. The immunology of glial neoplasms.
Apuzzo ML
Bull Los Angeles Neurol Soc; 1976 Oct; 41(4):176-83. PubMed ID: 74264
[TBL] [Abstract][Full Text] [Related]
17. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells.
Mamot C; Drummond DC; Greiser U; Hong K; Kirpotin DB; Marks JD; Park JW
Cancer Res; 2003 Jun; 63(12):3154-61. PubMed ID: 12810643
[TBL] [Abstract][Full Text] [Related]
19. Immunological aspects of experimental brain tumors (review).
Stavrou D; Bilzer T; Hultén M; Zänker KS; Anzil AP; Haglid KG; Dahme E
Anticancer Res; 1982; 2(3):151-5. PubMed ID: 6751209
[TBL] [Abstract][Full Text] [Related]
20. Regional localization of a glioma-associated antigen defined by monoclonal antibody 81C6 in vivo: kinetics and implications for diagnosis and therapy.
Blasberg RG; Nakagawa H; Bourdon MA; Groothuis DR; Patlak CS; Bigner DD
Cancer Res; 1987 Aug; 47(16):4432-43. PubMed ID: 3607773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
